Drug Profile
Palosuran
Alternative Names: ACT 058362; Urotensin II receptor antagonist - ActelionLatest Information Update: 27 Jun 2017
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Class Quinolines; Small molecules
- Mechanism of Action Urotensin II antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cardiovascular disorders; Diabetic nephropathies
Most Recent Events
- 16 Jun 2017 Actelion Pharmaceuticals was acquired by Janssen Pharmaceuticals
- 19 Jul 2012 Discontinued - Phase-II for Cardiovascular disorders in Switzerland (PO)
- 19 Jul 2012 Discontinued - Phase-II for Diabetic nephropathies in Switzerland (PO)